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SObjectives:Non small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality. Development
of an early diagnosis method may improve survivals. We aimed to develop a new diagnostic model for NSCLC
using serum biomarkers.
Methods:We set up a patient group diagnosed with NSCLC (n ¼ 122) and a healthy control group (n ¼ 225).
Thirty serum analytes were selected on the basis of previous studies and a literature search. An antibody-bead
array of 30 markers was constructed using the Luminex bead array platform (Luminex Inc, Austin, Tex) and was
analyzed. Each marker was ranked by importance using the random forest method and then selected. Using se-
lected markers, multivariate classification algorithms were constructed and were validated by application to in-
dependent validation cohort of 21 NSCLC and 28 control subjects.
Results: There was no difference in demographics between patients and the control population except for age
(64.8  10.0 for patients vs 53.0  7.6 years for the control group). Among the 30 serum proteins, 23 showed
a difference between the 2 groups (12 increased and 11 decreased in the patient group). We found the highest
accuracy of multivariate classification algorithms when using the 5 highest-ranked biomarkers (A1AT, CYFRA
21-1, IGF-1, RANTES, AFP). When we applied the algorithms on a validation cohort, each method recognized
the patients from the controls with high accuracy (89.8% with random forest, 91.8% with support vector ma-
chine, 88.2% with linear discriminant analysis, and 90.5% with logistic regression).
Conclusions: We confirmed that a new diagnostic method using 5 serum biomarkers profiling constructed by
multivariate classification algorithms could distinguish NSCLC from healthy controls with high accuracy.
(J Thorac Cardiovasc Surg 2012;143:421-7)G
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The Journal of Thoracic and Caremains poor despite major efforts to improve treatment
methods in the past decades. Difficulty in making an
early-stage diagnosis of lung cancer is a primary reason
for the lack of improvement in prognosis.1 Thus, identifica-
tion and validation of diagnostic and prognostic biomarkers
may improve the clinical outcome of lung cancer
treatments.2
Numerous candidate biomarkers have been reported for
risk assessment, screening, diagnosis, prognosis, and se-
lection and monitoring of therapies. Until now, the concen-
tration or amount of one or a few specific analytes has
been used as a score for considering a biomarker.3 How-
ever, it is difficult to explain a cancer through a single
gene mutation or a single protein disorder. For this reason,
high-throughput molecular tools such as microarrays have
been applied to find new classes of diseases to identify di-
agnostic markers for early detection and to predict progno-
sis.4 The Food and Drug Administration has used the
definition of in vitro diagnostic multivariate index assay
(IVDMIA) since 2007. With IVDMIA, the score is calcu-
lated from a number of measurement values such as gene
expression values and protein concentrations using the al-
gorithm.3 For example, MammaPrint of 70 genes in breast
cancer and Ova-1 protein in ovarian cancer are approved
as IVDMIAs and are applied in a real clinical
environment.rdiovascular Surgery c Volume 143, Number 2 421
Abbreviations and Acronyms
A1AT ¼ alpha-1 antitrypsin
ADC ¼ adenocarcinoma
AFP ¼ alpha-fetoprotein
Apo ¼ apolipoprotein
CYFRA ¼ cytokeratin fragment
IGF ¼ insulin-like growth factor
IVDMIA ¼ in vitro diagnostic multivariate index
assay
LDA ¼ linear discriminant analysis
LRM ¼ logistic regression
NSCLC ¼ non small cell lung cancer
pro-Apo ¼ pro-apolipoprotein
RANTES ¼ regulated upon activation normal T
cell expressed and secreted
RF ¼ random forest
SCC ¼ squamous cell carcinoma
SVM ¼ support vector machine
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SOur study aimed to identify several biomarkers of non
small cell lung cancer (NSCLC) and to construct prediction
models to diagnose NSCLC.PATIENTS AND METHODS
The Institutional Review Board of the Seoul National University Col
lege ofMedicine approved this study, and written informed consent was ob
tained from all patients for this study (IRB No. H 0910 005 295). From
October 2008 to March 2010, we collected blood samples from patients
who underwent curative surgery for NSCLC. All patients underwent cura
tive surgical resection and lymph node dissection. Whole blood samples
were gathered during the operation with the usual blood collecting
methods and were contained within SST II tubes (Becton Dickinson,
Franklin Lakes, NJ). After coagulation, with the tubes kept upright at
room temperature for 2 hours, sera were separated by centrifugation. All
the vials containing sera were immediately frozen in liquid nitrogen and
were stored at 80C until analysis. There were 69 adenocarcinomas
(ADCs) and 53 squamous cell carcinomas (SCCs). We gathered clinical
variables such as age, gender, pathologic TNM stage, cell type, differenti
ation, and size. A total of 225 blood samples collected from healthy persons
who visited the hospital for medical checkups and agreed to participate in
the study were used as a control for normal states. Serum separation and
storage procedure were the same as for the NSCLC group.
Selected Serum Proteins
We selected 30 serum markers from 55 original markers in this study.
Fifty five original markers were selected from 2 dimensional polyacryl
amide gel electrophoresis, surface enhanced laser desorption/ionization
time of flight mass spectrometry, and a literature search. Alpha 1 antitryp
sin (A1AT), apolipoprotein (Apo) A1, ApoA4, haptoglobin a, pro ApoA1,
and transthyretin were discovered with 2 dimensional polyacrylamide gel
electrophoresis. ApoH, beta 2 microglobulin, C reactive protein, free he
moglobin, serum amyloid A, and vitamin D binding protein were discov
ered using surface enhanced laser desorption/ionization time of flight mass
spectrometry. Forty three other proteins were selected through a literature
search. We used various combinations of keywords such as ‘‘cancer,’’
‘‘lung cancer,’’ ‘‘NSCLC,’’ ‘‘biomarker,’’ ‘‘marker,’’ ‘‘protein,’’422 The Journal of Thoracic and Cardiovascular Surg‘‘immunoassay,’’ and ‘‘review’’ using an electric database. From 55 origi
nal markers, we chose 30 proteins that were significantly differentially ex
pressed between the cancer and the normal controls in our pilot study with
4500 serum samples of 5 types of cancer (breast, colon, stomach, liver, and
lung).5 The list of selected analytes is shown in Table 1.
Multiplexed Bead-Based Immunoassay Procedure
We used multiplexed particle based flow cytometric assay methods to
measure the amount of serum analytes. Bead array kits or antibodies for
the construction of the plate were purchased from the following manufac
turers: Abcam (Cambridge, United Kingdom), Acris Affinity Bioreagents
Inc (Rockford, Ill), ALPCO (Salem, NH), Antibodies GmbH (Herford, Ger
many), Bethyl (Montgomery, Tex), Biodesign International (Saco, Maine),
Calbiochem (Merck, Darmstadt, Germany), Chemicon (Temecula, Calif),
DRG Diagnostics (Marburg, Germany), LabFrontier (Gyeonggi, Korea),
Millipore (Billerica, Mass), R&D Systems (Minneapolis, Minn), Rules
based Medicine (Austin, Tex), Santa Cruz Biotechnology Inc (Santa Cruz,
Calif), Sigma Aldrich (St Louis, Mo), and US Biological (Swampscott,
Mass). Luminex 200 (Luminex Inc, Austin, Tex) uses a sandwich immuno
assaywithfluorescent bead based technologyallowingmultiplex analysis of
up to 100 different analytes during a single process. Multiplex assaywas per
formed according to the manufacturer’s protocol described previously.5
Statistical Analysis
The Student t test was used to evaluate the significance of differences in
individual serum biomarker levels expressed between the NSCLC group
(n 122) and the healthy control group (n 225). For multivariate anal
ysis of biomarker combinations, we used various analytic methods (random
forest [RF], support vector machine [SVM], linear discriminant analysis
[LDA], and logistic regression [LRM]). From a total number of 347 sam
ples, we used 249 samples that had measured values of all 30 analytes.
For constructing the classification algorithms, 121 NSCLC samples and
128 control samples were divided between the model developing sets
(100 in the NSCLC and 100 in the control) and the validation sets (21 in
the NSCLC and 28 in the control). Each marker was ranked by importance
using the RF method and put into modeling according to their ranking. For
importance ranking, 70 samples from each group were randomly selected
100 times, and average scores of 100 times importance were used. After
ranking, 70 samples from each group were randomly assigned to the train
ing sets, and the remaining 30 samples were assigned to the test sets. We
constructed models in the training set and applied to the test set. Models
were made with all possible combinations of selected markers to select
the most ideal marker set. Final validation was applied to the validation
set that was independent of the construction of the model. This 3 step pro
cedure was repeated 50 times with changing training sets. We also changed
the total number of markers put into modeling and compared the results
with the receiver operating characteristic curve and the area under the curve
(Figure E1). The modeling procedure was shown in Figure 1. All calcula
tions were performed using the R software (http://www.r project.org/).RESULTS
Clinical Characteristics
There were 122 NSCLC samples (ADC, 69; SCC, 53)
and 225 healthy control samples. There were 79 men
(64.8%), and the mean age of the patients was 64.8 years
(standard deviation, 10.0 years) in the NSCLC group. There
was a difference in age between the patients and the control
population (64.8  10.0 for patients vs 53.0  7.6 years for
control group; P<.01). The most common stage of cancer
was stage 1 (68.8%). Table 2 shows the clinical information
of 249 samples used in modeling procedures.ery c February 2012
FIGURE1. Schematic diagram of themodeling procedure.NSCLC,Non
small cell lung cancer.
TABLE 1. List of biomarkers selected for multiplexed bead-based
assay
Category Individual biomarkers
Cancer antigens/oncogenes Alpha fetoprotein (AFP)
Carcinoembryonic antigen (CEA)
Cancer antigen 125 (CA 125)
Cancer antigen 19 9 (CA 19 9)
Cytokeratin fragment 21 1 (CYFRA 21 1)
Free prostate specific antigen (fPSA)
Total prostate specific antigen (tPSA)
Cytokines/chemokines Interleukin 6 (IL 6)
Regulated upon activation normal T cell
expressed and secreted (RANTES)
Growth/angiogenic factors Epidermal growth factor receptor (EGFR)
Insulin like growth factor 1 (IGF 1)
Acute phase protein Alpha 1 antitrypsin (Al AT)
Alpha 2 macroglobulin (A2M)
C reactive protein (CRP)
D dimer (DD)
Haptoglobin alpha (Hp)
Transthyretin (TTR)
Coagulation Hemoglobin
Metabolism Apolipoprotein Al (ApoAl)
Apolipoprotein A2 (ApoA2)
Apolipoprotein A4 (ApoA4)
Apolipoprotein C2 (ApoC2)
Apolipoprotein C3 (ApoC3)
Pro apolipoprotein Al (proApoAl)
Metastasis related
molecules
Plasminogen activator inhibitor 1 (PAI 1)
Adhesion molecules Soluble intercellular cell adhesion
molecule 1 (sICAM 1)
Soluble vascular cell adhesion molecule 1
(sVCAM 1)
Vitronectin (VN)
Immune/inflammation Beta 2 microglobulin (B2M)
Other proteins Vitamin D binding protein (VDBP)
TABLE 2. Patients’ characteristics
Variables
Lung cancer
(n 121)
Healthy control
(n 128)
Sex (M/F) 78 (64.5%)/43
(35.5%)
78 (60.9%)/50
(39.1%)
Age (y, mean  SD) 64.7  9.9 (35 86) 50.3  6.2 (41 65)
Cell type
Adenocarcinoma 68 (56.2%)
Squamous cell 53 (43.8%)
Pathologic stage
IA 33 (27.3%)
IB 50 (41.3%)
IIA 2 (1.7%)
IIB 12 (9.9%)
IIIA 13 (10.7%)
IIIB 8 (6.6%)
IV 3 (2.5%)
Tumor size
(long diameter, cm)
3.4  1.9 (0.8 10.0)
Lymph node status
N0 89 (73.6%)
N1 14 (11.6%)
N2 15 (12.4%)
N3 3 (2.5%)
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Table 3. Twenty-three proteins showed a difference be-
tween the 2 groups. A1AT, alpha-fetoprotein (AFP), cancer
antigen 125, cancer antigen 19-9, carcinoembryonic anti-
gen, C-reactive protein, cytokeratin fragment (CYFRA)
21-1, D-dimer, hemoglobin, insulin-like growth factor
(IGF)-1, interleukin 6, and total prostate-specific antigen
were increased, whereas alpha-2 macroglobulin, ApoA1,
ApoC2, ApoC3, epidermal growth factor receptor, plasmin-
ogen activator inhibitor-1, pro-ApoA1, regulated upon acti-
vation normal T cell expressed and secreted (RANTES),
soluble vascular cell adhesion molecule-1, transthyretin,
and vitronectin were decreased in the patient group.Differentiation
Well 60 (49.6%)
Moderate 45 (37.2%)
Poor 14 (11.6%)
Unknown 2 (1.7%)Multivariate Classification Algorithm
We performed a multivariate classification algorithm
with 121 NSCLC samples and 128 control samples.The Journal of Thoracic and CaSamples were divided into 3 groups: training, test, and val-
idation sets. The details are given in the Materials and
Methods section. Among 30 proteins, hemoglobin,
D-dimer, and interleukin 6 were excluded because those
proteins could have been affected by the surgical procedure
itself.6-13 We selected the highest-ranked proteins in orderrdiovascular Surgery c Volume 143, Number 2 423
TABLE 3. Comparison of plasma protein markers between non–small cell lung cancer and healthy controls
Markers Unit
Lung cancer Healthy control
P valueN Median Q1-Q3 N Median Q1-Q3
A1AT (mg/mL) 122 14 5.6 30 225 2.3 1.8 2.9 .003
A2M (mg/mL) 122 43 29 61 225 60 42 85 <.001
AFP (ng/mL) 122 2.3 1.3 3.1 225 0.46 0.11 1.2 <.001
ApoA1 (mg/mL) 122 0.29 0.19 0.37 225 0.41 0.30 0.52 <.001
ApoA2 (mg/mL) 122 0.30 0.24 0.37 225 0.31 0.28 0.36 .587
ApoA4 (mg/mL) 122 10 7.6 15 225 12 8.6 15 .508
ApoC2 (mg/mL) 122 90 60 110 225 120 90 140 .002
ApoC3 (mg/mL) 122 0.19 0.13 0.23 225 0.23 0.19 0.28 <.001
B2M (mg/mL) 122 1.7 1.3 2.1 225 1.8 1.5 2.2 .162
CA 125 (U/mL) 122 3.8 1.0 9.6 225 1.1 1.0 3.3 <.001
CA 19 9 (UmL) 122 8.1 4.1 13 225 3.0 1.3 5.1 <.001
CEA (ng/mL) 122 2.4 1.7 4.3 225 1.2 0.74 2.2 <.001
CRP (mg/mL) 122 4.4 1.3 12 225 1.8 0.85 4.5 .004
CYFRA21 1 (ng/mL) 121 1.3 0.66 2.4 129 0.010 0.010 0.73 <.001
D dimer (mg/mL) 122 6.0 3.1 19 225 2.6 2.0 3.6 <.001
EGFR (ng/mL) 121 32 27 38 153 43 38 46 <.001
Hemoglobin (ng/mL) 122 500 130 3700 225 8.3 5.0 33 <.001
Hp (mg/mL) 122 1.0 0.74 1.6 225 1.1 0.82 1.5 .473
IGF 1 (ng/mL) 121 1.9 1.0 3.4 134 0.31 0.070 0.81 <.001
_IL 6 (ng/mL) 122 30 13 87 225 1.8 0.90 3.3 .010
PAI 1 (mg/ml) 122 0.83 0.63 1.0 225 1.2 0.95 1.4 <.001
proApoAl (mg/mL) 122 12 6.0 18 225 23 18 28 <.001
fPSA (ng/mL) 122 0.15 0.10 0.47 225 0.078 0.012 0.24 .056
tPSA (ng/mL) 122 0.35 0.010 1.1 225 0.27 0.014 0.63 .006
RANTES (ng/mL) 122 43 29 58 225 74 58 92 <.001
sICAM 1 (mg/mL) 122 0.12 0.096 0.16 225 0.13 0.10 0.15 .523
sVCAM 1 (mg/mL) 122 0.93 0.76 1.1 225 1.1 0.94 1.2 <.001
TTR (mg/mL) 122 0.25 0.21 0.31 225 0.34 0.28 0.39 <.001
VDBP (mg/mL) 122 0.18 0.13 0.22 225 0.23 0.20 0.26 .853
VN (mg/mL) 122 92 74 110 225 98 86 110 .005
A1AT,Alpha-1 antitrypsin; A2M, alpha-2 macroglobulin; AFP, alpha-fetoprotein; Apo, Apolipoprotein; B2M, beta-2 microglobulin; CA, cancer antigen; CEA, carcinoembryonic
antigen; CRP,C-reactive protein; CYFRA, cytokeratin fragment; EGFR, epidermal growth factor receptor;Hp, haptoglobin alpha; IGF, insulin-like growth factor; IL, interleukin;
PAI, plasminogen activator inhibitor; proApo, pro-apolipoprotein; fPSA, free prostate-specific antigen; tPSA, total prostate-specific antigen; RANTES, regulated upon activation
normal T cell expressed and secreted; sICAM-1, soluble intercellular adhesion molecule; sVCAM, soluble vascular cell adhesion molecule; TTR, transthyretin; VDBP, vitamin
D–binding protein; VN, vitronectin.
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gorithms were constructed from selected markers using 4
analytical methods. We found the greatest accuracy of mul-
tivariate classification algorithms when using the 5 highest-
ranked biomarkers (A1AT, CYFRA 21-1, IGF-1, RANTES,TABLE 4. Multivariate classification algorithm; random forest, support v
Algorithm Markers
Accuracy (%)
Train Valid
RF A1AT, CYFRA 21 1, IGF 1,
RANTES, AFP
94.3 89.8
SVM A1AT, CYFRA 21 1, IGF 1,
RANTES
96.6 91.8
LDA A1AT, CYFRA 21 1, IGF 1,
RANTES, AFP
94.1 88.2
LRM A1AT, CYFRA 21 1, IGF 1,
RANTES
95.2 90.5
NPV, Negative predictive value; PPV, positive predictive value; Train, training set; Valid,
424 The Journal of Thoracic and Cardiovascular Surgand AFP) (Table 4). When we applied the algorithms on
a validation cohort, each method recognized the NSCLC
patients from the normal controls with high accuracy
(89.8% with RF, 91.8% with SVM, 88.2% with LDA,
and 90.5% with LRM). On the receiver operatingector machine, linear discriminant analysis, and logistic regression
Sensitivity (%) Specificity (%) PPV NPV
Train Valid Train Valid (%) (%)
94.8 80.3 93.8 99.3 94.9 93.1
97.1 85.7 96.0 97.8 95.0 93.8
92.7 82.6 95.4 93.9 94.8 91.7
95.7 85.1 94.8 95.9 93.4 93.8
validation set. For other abbreviations, see Table 3.
ery c February 2012
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Scharacteristic curve, the areas under the curve of the algo-
rithm were 0.991 with RF, 0.984 with SVM, 0.987 with
LDA, and 0.982 with LRM (Figure E1). The correlation
of the markers to the final model is shown in Figure E2.
A1AT, CYFRA 21-1, IGF-1, and AFP increased the ten-
dency of cancer with higher serum concentrations. We ana-
lyzed the sensitivity of our algorithms according to
histologic type. The sensitivity of SCCwas better compared
with that of ADC (96.2% in SCC vs 89.7% in ADC with
RF) (Table E2). The incidence of incorrect diagnosis was
1 in SCC and 8 in ADC. Incorrect diagnosis was not related
to pathologic stage, tumor size, differentiation, or R0
resection.
DISCUSSION
Biomarkers of NSCLC can be obtained from several ma-
terials such as sputum, blood, and lung cancer tissue. In this
study, we used serum rather than lung cancer tissue because
it is easily acquired via a less invasive approach, which is
very important in a clinical setting.
Multiplexed bead-based flow cytometric assay is used in-
creasingly with high-throughput analysis. Polystyrene/latex
microspheres of 3- to 5-mm diameter were used to detect
a reaction between serum analytes and antibodies. The flu-
idity also increases the chance of reaction. The variety of
size of beads and intensity of fluorescence make multiple
analytic processes possible simultaneously. This method
has been used widely not only in oncology but also for im-
mune diseases, infectious diseases, and diagnosis of stroke
with accurate measurement of cytokines and immunoglob-
ulin.14 The range of observational errors is known to be not
large,15 and in this study, intra-assay precision ranged from
2% to 16% and interassay precision ranged from 6% to
19% during the experiment. Gorelik and associates16
used this analytic method to construct a diagnostic model
using interleukins 6 and 8, vascular endothelial growth fac-
tor, epidermal growth factor, and cancer antigen 125; they
reported 84% sensitivity and 95% specificity. Linkov and
colleagues17 also used a flow cytometric assay to diagnose
head and neck cancer using 25 serum biomarkers and re-
ported 84.5% sensitivity and 98% specificity. However,
for NSCLC, no previous studies have used this method.
Of a total number of 347 samples, we used 249 samples
that had measured values of all 30 analytes in modeling pro-
cedures. Although the gender ratiowas similar between the 2
groups, the control group was about 14 years younger than
the cancer group. To see the effect of age, we analyzed serum
biomarkers according to age in the control group. We com-
pared the mean concentration of analytes among subjects
in their 40s, 50s, and 60s using analysis of variance. There
was no differences except b2-microglobulin (P < .01),
pro-ApoA1 (P ¼ .01), and soluble vascular cell adhesion
molecule-1 (P<.01), which increased in elder age.However,
those 3 markers were not included in our final model.The Journal of Thoracic and CaIn IVDMIA, the score is calculated from a number of
measurement values, and the algorithm, the method of cal-
culating the score, is critical.3 We used 4 analytic methods
for the score-calculating algorithm. In LRM, overfitting is
problematic, especially when the sample size is small and
there are many variables in 1 model.18 RF is known to be
superior in minimizing this weakness with the random in-
puts and classification trees as much as possible without
variable deletion.19,20 We used the 5 highest-ranked bio-
markers rather than all 27 biomarkers in modeling. Al-
though it is difficult to define the ideal number that is
included in modeling, it is practical to reduce the number
of biomarkers if the same accuracy can be achieved. We
constructed the models by reducing the total number of an-
alytes and selected the ideal model considering accuracy
and area under the curve of the training set. We validated us-
ing the validation set, and it was confirmed with high accu-
racy (89.8% with RF, 91.8% with SVM, 88.2% with LDA,
and 90.5% with LRM). We used only 1 validation cohort in
this study, so we attempted to overcome this limitation by
repeating modeling 50 times within estimation sample set.
According to analytic methods, the results are relatively
constant.
In our algorithm, SCC showed better sensitivity than did
ADC (96.2% in SCC vs 89.7% in ADC with RF) (Table
E2). Inasmuch as the purpose of our model was to diagnose
lung cancer, we did not include cell type as a factor. How-
ever, to predict prognosis, consideration of cell type may
be necessary. Most SCC patients were smokers (94.3%),
whereas only 26.5% of ADC patients were smokers. Inas-
much as cell type and smoking are closely related, we
also have to consider smoking effect. In this study, we could
not analyze smoking factors owing to lack of smoking status
in the normal group. The final model was developed with
A1AT, CYRFA 21-1, IGF-1, RANTES, and AFP. By the
model, 9 in the cancer group and 6 in the control group
were erroneously classified among 249 samples. According
to the cell types of NSCLC, ADC was more frequently mis-
classified than SCC (ADC, 8; SCC, 1). According to the
stage, there was no difference in terms of incorrect diagno-
sis. After surgery, 11 patients had recurrence of lung cancer.
When we compared the model score according to the recur-
rence, there was no difference between the group with re-
currence and the group without recurrence (recurrence
group, 0.913  0.03; nonrecurrence group, 0.869  0.02),
which suggested that our model might not be good for prog-
nostic prediction.
According to the RF importance, A1AT is highly ex-
pressed in both ADC and SCC, whereas IGF-1 and
RANTES is highly expressed in ADC, and CYFRA 21-1
and AFP is highly expressed in SCC.
A1AT is a glycoprotein and an antagonist of serum tryp-
sin. In the body, A1AT is elevated in the acute inflammatory
phase to protect tissues from digestive enzymes (especiallyrdiovascular Surgery c Volume 143, Number 2 425
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Selastase) produced by inflammatory cells. A1AT deficiency
is related to destructive congenital lung parenchymal dis-
ease. Hamrita and coworkers21 reported elevated A1AT
levels in patients with invasive breast cancer.
CYFRA 21-1 (cytokeratin 19 fragment) is reported as be-
ing related to lung cancer. Lai and associates22 reported that
a high serum level of CYFRA 21-1 is related to the ad-
vanced stage and poor prognosis in SCC. Pujol and col-
leagues23 meta-analyzed 2063 patients and reported that
serum concentrations of more than 3.6 ng/mL showed
a lower survival than those with less and the hazard ratio
was 1.88. This study also showed a high serum level of CY-
FRA 21-1 in SCC patients.
IGF-1 is reported to be related to multiple cancers such as
endometrial cancer, breast cancer, ovarian cancer, gastric
cancer, pancreatic cancer, colon cancer, and lung cancer.24
Inasmuch as IGF-1 is a primary mediator of growth hor-
mone, it relates to growth and differentiation of the cell
and to apoptosis.
In summary, we confirmed that our new diagnostic
method using 5 serum biomarkers profiling constructed
by multivariate classification algorithms could distinguish
persons with NSCLC from healthy controls with high accu-
racy. Additional future study of a larger population is nec-
essary to prove the usefulness of this method for early
diagnosis for NSCLC.
We acknowledge Hyun Cho Wi, Yoo Jin Jung, and Yung Min
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Dr Daniel Kreisel (St Louis, Mo). Congratulations on a very
nice presentation and a nice study. Thank you for allowing me to
review your manuscript in a timely fashion.
Your study addresses an important issue in thoracic oncology,
the identification of biomarkers, which would ideally allow us to
accurately identify patients with lung cancer in a cost effective
and practical manner. Your study extends numerous previous stud
ies that have used profiling of serum markers in an attempt to de
tect patients who harbor malignancies, including ovarian cancers.
I have 3 questions. You opted to draw the blood from the pa
tients during surgery, whereas blood from healthy controls was ob
tained during routine office visits. Inasmuch as inflammatory
responses can affect some of your markers, such as RANTES,
the obvious question is how you account for the confounding fac
tor of stress associated with surgery or anesthesia in your study
population.
Dr Lee. Thank you, Dr Kreisel, for your very important
question.
Our lung cancer samples were collected during surgery after
general anesthesia. We excluded several biomarkers from the final
modeling to minimize the surgical effect. It is a limitation of our
study.We excluded 3markers: D dimer, hemoglobin, and interleu
kin 6. In our additional study of postoperative samples, the scores
calculated with this algorithm had not fallen yet at 3 postoperative
months. That was encouraging, because if the algorithm resultsery c February 2012
Lee et al General Thoracic Surgerymight have been affected owing to surgical effect, the scores
should have fallen by that time. Despite that result, we are planning
to study further and we are collecting new samples for the next
step studies to compare between the lung cancer group and the be
nign lung disease group or to compare between the early cancer
group and the advanced cancer group.
Dr Kreisel.How do you suggest your findings should be imple
mented into clinical practice? Which population would you con
sider for screening with these biomarkers? Where do you see the
value of the biomarkers compared with screening computed tomo
graphic scans? I would also like you to comment on the cost aspect
of this assay.
Dr Lee. In this study, about 70%were pathologic stage I. There
fore, patients with surgically resectable, early stage lung cancer
were the most targeted population in this study. However, as I
mentioned earlier, the role of this algorithm in the screening of
high risk patients should be studied further. In as much as com
puted tomographic screening shows a relatively high false positive
rate, it may be helpful in that situation. For the price, it may be
lower to test many samples in one plate simultaneously, but it is
difficult to say at this time.
Dr Kreisel. There are extensive standard deviations with this
assay, both in your hands and in multiple other studies. Could
you comment on how reproducible you think this assay would
be if it were to be implemented in the clinical practice?
Dr Lee. Reproducibility is a very important and very difficult
issue in molecular biology. We also considered and kept someThe Journal of Thoracic and Casamples for final validation instead of entering them into the mod
eling procedure, and we used 4 analytical methods to overcome,
but we know it is not enough. To generalize this result to lung can
cer, a further larger study should be done, including a randomized
clinical trial. I think that a long process should be done.
Dr David H. Harpole, Jr (Durham, NC). This is a very nice
study.
My only comment is that we and others for many years have
been looking at serum markers predictive of lung cancer. You cor
rectly state in your last conclusion that there are probably hundreds
of articles in the literature on serum markers that can separate nor
mal controls from lung cancer patients, but when one takes a group
of patients with suspicious lung nodules who are smokers, most of
them go away, because, frankly, the differential of those patients
tends to be closer. That is an important point.
Second, the value of the beads is that they allow you to look si
multaneously at a lot of the markers, and you have done some el
egant modeling to reduce the number of markers. However, the
problem with that is that when we are looking at ADC and SCC,
they can be different. I think you have a good technology here.
You may want to remodel this, frankly, with all of your markers,
so that when you are looking at it with smokers, you may see dif
ferent ones fall in and out depending on the patients, and it may
prove it to be more predictive. That is the real power of this tech
nology allowing you to see 30 markers at once.
Dr Lee. We considered the clinical practice. We did use just
a number of biomarkers. That is a good comment.rdiovascular Surgery c Volume 143, Number 2 427
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FIGURE E1. The multivariate classification algorithm using the 5 highest ranked biomarkers. A, The area under the curve was calculated for the final
selected algorithm. B, The 249 samples were distinctly classified using the algorithm. Scores closer to 0 are normal and scores closer to 1 are malignant
on the y axis. NSCLC, Non small cell lung cancer; RF, Random forest; SVM, support vector machine; LDA, linear discriminant analysis; LRM, logistic
regression; AUC, area under the curve.
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FIGUREE2. The partial dependence plot using the 5 highest ranked biomarkers. A1AT, CYFRA 21 1, IGF 1, and AFP increased likelihood of cancer with
higher serum concentrations while RANTES decreased. A1AT, Alpha 1 antitrypsin; CYFRA, cytokeratin fragment; IGF, insulin like growth factor; AFP,
alpha fetoprotein.
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TABLE E1. Ranking of each marker according to its importance
using random forest method
Total Importance Rank
A1AT 0.059398 1
CYFRA21-1 0.052887 2
IGF-1 0.051408 3
RANTES 0.026415 4
AFP 0.025287 5
proApoAI 0.020325 6
EGFR 0.011263 7
TTR 0.010751 8
CEA 0.010563 9
PAI-1 0.009198 10
VDBP 0.007086 11
CA 19-9 0.005754 12
A2M 0.004818 13
ApoC3 0.004689 14
ApoA1 0.004026 15
ApoC2 0.003951 16
sVCAM-1 0.002140 17
fPSA 0.002094 18
CRP 0.002044 19
tPSA 0.001857 20
CA 125 0.001852 21
VN 0.001125 22
ApoA2 0.001091 23
Hp 0.000423 24
B2M 0.000176 25
slCAM-1 0.000138 26
ApoA4 0.000047 27
A1AT, Alpha-1 antitrypsin; CYFRA, cytokeratin fragment; IGF, insulin-like growth
factor; RANTES, regulated upon activation normal T cell expressed and secreted;
AFP, alpha-fetoprotein; proApo, pro-apolipoprotein; EGFR, epidermal growth factor
receptor; TTR, transthyretin; CEA, carcinoembryonic antigen; PAI, plasminogen
activator inhibitor; VDBP, vitamin D–binding protein; CA, cancer antigen; A2M,
alpha-2 macroglobulin; Apo, apolipoprotein; sVCAM, soluble vascular cell adhesion
molecule; fPSA, free protein-specific antigen; CRP, C-reactive protein; tPSA, total
protein-specific antigen; VN, vitronectin; Hp, haptoglobin alpha; B2M, beta-2
microglobulin; sICAM, soluble intercellular adhesion molecule.
TABLE E2. Multivariate classification algorithms; adenocarcinoma versus squamous cell carcinoma
Algorithm Markers
Adenocarcinoma Squamous cell Overall
Sensitivity (%) Sensitivity (%) Sensitivity (%)
RF A1AT, CYFRA 21-1, IGF-1, RANTES, AFP 89.7 (61/68) 96.2 (51/53) 92.6 (112/121)
SVM A1AT, CYFRA 21-1, IGF-1, RANTES, AFP 88.2 (60/68) 96.2 (51/53) 91.7 (111/121)
LDA A1AT, CYFRA 21-1, IGF-1, RANTES, AFP 83.8 (57/68) 100 (53/53) 90.9 (110/121)
LRM A1AT, CYFRA 21-1, IGF-1, RANTES, AFP 86.8 (59/68) 98.1 (52/53) 91.7 (111/121)
RF, Random forest; SVM, support vector machine; LDA, linear discriminant analysis; LRM, logistic regression. For other abbreviations, see Table E1.
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